Biotechnology
CartiHeal Announces Pivotal Study Results Demonstrate Agili-C™ Superiority to Microfracture and Debridement for the Treatment of Cartilage and Osteochondral Defects
According to a Two-Year Randomized and Controlled Multinational IDE Study KFAR SABA, Israel, Aug. 3, 2021 /PRNewswire/ -- CartiHeal Ltd, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, which was granted Breakthrough Device...
2021-08-03 20:06
1992
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans
Yvelise Barrios, MD, PhD, Immunologist and leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behindCoviDTH, joins BioVaxys as scientific adviser VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (C...
2021-08-03 20:00
4917
Angel Yeast Reports Strong Revenue Growth in First Half of 2021, Achieves 20.55% YoY Increase
YICHANG, China, Aug. 3, 2021 /PRNewswire/ -- Angel Yeast Co., Ltd ("Angel Yeast
")(en.angelyeast.com
2021-08-03 15:54
2385
Nanoform and Boehringer Ingelheim execute master services agreement
HELSINKI, Aug. 3, 2021 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform's award-winning CESS® technology can deliver to its drug development proj...
2021-08-03 14:28
2162
GenScript Joins Forces with Allozymes by Providing Smart Libraries Construction for Precision Protein Engineering
SINGAPORE, Aug. 3, 2021 /PRNewswire/ -- GenScript Biotech Corporation (Stock Code: 1548.HK) today announced a collaboration with Allozymes, a synthetic biology company transforming ingredient manufacturing by unlocking protein engineering potential through groundbreaking technologies. In this par...
2021-08-03 12:05
8562
CStone announces positive registrational study of the first-in-class drug ivosidenib in Chinese patients with relapsed or refractory acute myeloid leukemia, and NDA has been accepted by the China NMPA and considered for Priority Review
* Ivosidenib (TIBSOVO®, the brand name in the U.S.) is the first isocitrate dehydrogenase 1 (IDH1) inhibitor inChina that has demonstrated its efficacy and manageable safety in patients with relapsed or refractory acute myeloid leukemia (R/R AML) * The National Medical Products Administration...
2021-08-03 08:05
3451
WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate
SUZHOU, China, Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP c...
2021-08-02 20:13
3282
Happiness Biotech Announced Financial Results for Fiscal Year Ended March 31, 2021
NANPING, China, Aug. 2, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer and e-commerce services provider, today announced its financial results for the fiscal year endedMarch 31, 2021. F...
2021-08-02 20:00
28766
Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets
* Nitric oxide has antimicrobial properties with direct proven effect on SARS-CoV-2 * Nitric Oxide Nasal Spray (NONS) has been tested in healthy volunteers and patients as part of UK andCanada clinical trials1 MUMBAI, India and VANCOUVER, BC, Aug. 2, 2021 /PRNewswire/ -- Glenmark Pharmaceutic...
2021-08-02 18:45
3227
ElectroPhysiology Frontiers announces appointment of Avi Fischer, M.D. as CEO
MILAN, Aug. 2, 2021 /PRNewswire/ -- ElectroPhysiology Frontiers S.p.A. (EPF), announced that its Board of Directors unanimously appointedAvi Fischer, M.D. as Chief Executive Officer (CEO) of the company and a member of its Board of Directors. EPF is a medical technology company developing an inn...
2021-08-02 18:00
2034
Bionomics Announces Plans to Conduct U.S. Initial Public Offering
ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United ...
2021-08-02 18:00
13882
Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers
HOUSTON and SINGAPORE, Aug. 2, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...
2021-08-02 17:00
1469
BIOKANGTAI COVID-19 Vaccine Approved for Phase III Clinical Trial in the Philippines
SHENZHEN, China, Aug. 2, 2021 /PRNewswire/ -- On July 30, Shenzhen Kangtai Biological Products Co., Ltd. (BIOKANGTAI) was approved by the Philippine Food and Drug Administration (PFDA) to launch the phase III clinical trial of its independently developed Inactivated COVID-19 Vaccine (Vero cells) ...
2021-08-02 15:25
5170
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
TIBSOVO is the first targeted therapy to show improved event-free survival and overall survival in combination with azacitidine compared to azacitidine monotherapy. Safety profile consistent with previously published data in patients with IDH1-mutated acute myeloid leukemia. The study recently ...
2021-08-02 14:00
2322
LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic
SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH). ...
2021-08-02 11:11
1363
Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics i...
2021-08-02 07:29
5820
Appendix 4C - Q4 FY21 Quarterly Cash Flow Report
Highlights: * Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial * Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein related neurodegeneration in MSA animal model * Presents to MST Access Australian Micro & Small Caps Conference ...
2021-07-30 21:05
14683
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
* Planning underway for a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid protein plaques in Alzheimer's Disease SHANGHAI and GAITHERSBURG, Md., July 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage bio...
2021-07-30 20:00
8748
EC Healthcare and Prenetics Form Strategic Partnership to Pioneer the Future of Medicine
HONG KONG, July 30, 2021 /PRNewswire/ -- EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group inHong Kong, announces that the Group signed a memorandum of understanding with Prenetics Limit...
2021-07-30 15:33
9295
Neukio Biotherapeutics completed its $40m Angel round financing, focusing on the development of iPSC-CAR-NK platform and assets.
SHANGHAI, July 30, 2021 /PRNewswire/ -- Neukio Biotherapeutics, a newly established company, recently announced the completion of its$40m Angel round of financing led byLilly Asia Venture (LAV), with the participation of IDG Capital and Sherpa Investments. The fund will be used mainly for the es...
2021-07-30 08:00
2527
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
